Nick Thakore and Bob Ewing, co-heads of U.S. equities, discuss small- and large-cap stock performance in the biotech sector.

A Boston-area biotech firm could be closing in on a possible cure for Alzheimer's. Fortune magazine profiles Biogen in its latest issue, and Leigh Gallagher joins Morning Joe to discuss why the firm may be closing in on a cure.

Dr. Richard Pazdur, director of FDA's Office of Hematology and Oncology Products, tells BioCentury why the FDA is racing to approve new cancer drugs. Dr. Pazdur says new targeted drugs and immunotherapies with unprecedented efficacy are the payoff from 20 years of basic science. He calls for greater patient engagement in drug development, says compassionate access should be improved, and predicts rapid uptake of biosimilars.

Today's video highlights include AstraZeneca, Onglyza, Kombiglyze, Takeda, Nesina, FDA, Pfizer, Ibrance, tremelimumab, Merck & Co., NewLink Genetics and rVSV-ZEBOV.

Biotech valuations may be relatively high in some cases, but on the whole they are not overly stretched and certainly not in bubble territory, said Marshall Gordon, Senior Research Analyst at ClearBridge Investments.

FierceBiotech Editor-in-Chief John Carroll sits down with Bloomberg Intelligence analyst Asthika Goonewardene to discuss biotech's big year and whether it's sustainable.

A look at the NASDAQ Biotech index. Is there a bubble? Austrian Markets looks at the data.

At the University of Pennsylvania, a research team has been working on an experimental treatment to kill leukemia with a patient's own immune system cells. So far, the results have shown startling success. Special correspondent Jackie Judd reports on the growing research on immunotherapy in fighting cancer.

William Blair Managing Director Daniel Shedivy talks about what the upsurge in M&A means for the healthcare sector.

Healthcare analyst Michael Douglass and healthcare contributor Todd Campbell discuss the pitfalls and potential of two small-cap biotech stocks.

Today's video highlights include Takeda, Bristol-Myers Squibb, Bavarian Nordic, Prostvac, Yervoy, Orexigen Therapeutics, Contrave, FDA, Pfizer, Prevenar 13 and the European Commission.

Analysts Michael Douglass and Todd Campbell discuss two small biotechs that recently reported hepatitis C data and look at their opportunity in this large and competitive market.